Cite
Correction: Liu et al. Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. J. Clin. Med. 2023, 12 , 1861.
MLA
Liu, Yang, et al. “Correction: Liu et Al. Endostatin 33 Peptide Is a Deintegrin Α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. J. Clin. Med. 2023, 12 , 1861.” Journal of Clinical Medicine, vol. 13, no. 13, July 2024. EBSCOhost, https://doi.org/10.3390/jcm13133943.
APA
Liu, Y., Wang, C.-L., Pang, Z.-Q., Gao, K., Shen, L.-K., Xu, W.-H., & Ren, M.-H. (2024). Correction: Liu et al. Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. J. Clin. Med. 2023, 12 , 1861. Journal of Clinical Medicine, 13(13). https://doi.org/10.3390/jcm13133943
Chicago
Liu, Yang, Chang-Lin Wang, Zhong-Qi Pang, Ke Gao, Lin-Kun Shen, Wan-Hai Xu, and Ming-Hua Ren. 2024. “Correction: Liu et Al. Endostatin 33 Peptide Is a Deintegrin Α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. J. Clin. Med. 2023, 12 , 1861.” Journal of Clinical Medicine 13 (13). doi:10.3390/jcm13133943.